Zhengyu Yuan
Overview
Explore the profile of Zhengyu Yuan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
155
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhao X, Huang H, Yuan H, Yuan Z, Zhang Y
J Antimicrob Chemother
. 2022 Aug;
77(11):3210-3211.
PMID: 35972415
No abstract available.
2.
Liu J, Wang W, Wang C, Zhang L, Zhang X, Liu S, et al.
ACS Med Chem Lett
. 2022 Jul;
13(7):1030-1035.
PMID: 35859881
New oral antibiotic contezolid (CZD) is effective against Gram-positive infections but unsuitable for intravenous (IV) administration due to its modest solubility. To address the medical need for an IV form...
3.
Yuan H, Wu H, Zhang Y, Huang H, Li Y, Wu J, et al.
Antimicrob Agents Chemother
. 2022 May;
66(6):e0243021.
PMID: 35575579
This study aimed to build a population pharmacokinetic (PopPK) model for contezolid tablet (MRX-I) in healthy subjects and adults with complicated skin and soft-tissue infections (cSSTIs) to further evaluate the...
4.
Zhao X, Huang H, Yuan H, Yuan Z, Zhang Y
J Antimicrob Chemother
. 2022 Mar;
77(6):1762-1769.
PMID: 35265985
Objectives: Contezolid is a novel oxazolidinone antibacterial agent for managing infections caused by aerobic and anaerobic Gram-positive bacteria including methicillin-resistant strains. A Phase III, multicentre, randomized, double-blind, active-controlled trial evaluated...
5.
Meng J, Zhong D, Li L, Yuan Z, Yuan H, Xie C, et al.
Drug Metab Dispos
. 2015 Feb;
43(5):646-59.
PMID: 25710940
MRX-I is an analog of linezolid containing a 2,3-dihydropyridin-4-one (DHPO) ring rather than a morpholine ring. Our objectives were to characterize the major metabolic pathways of MRX-I in humans and...
6.
Huang Y, Xu Y, Liu S, Wang H, Xu X, Guo Q, et al.
Int J Antimicrob Agents
. 2014 Apr;
43(5):418-22.
PMID: 24721233
MRX-I is a new oxazolidinone antimicrobial under development. In this study, the potential for development of resistance to MRX-I in Staphylococcus aureus was investigated and key mutations were characterised. Determination...
7.
Wang W, White R, Yuan Z
Antimicrob Agents Chemother
. 2006 Apr;
50(5):1656-63.
PMID: 16641432
Peptide deformylase (PDF) is an essential enzyme in both gram-negative and gram-positive bacteria. It hydrolyzes formylated N-terminal peptides to generate free N-terminal peptides during the process of protein maturation. Inhibition...
8.
Yuan Z, White R
Biochem Pharmacol
. 2005 Nov;
71(7):1042-7.
PMID: 16289392
Although peptide deformylase (PDF, EC 3.5.1.27) was first described in 1968, the instability of enzyme preparations prevented it from being seriously considered as a target until this problem was finally...
9.
Dean C, Narayan S, Daigle D, Dzink-Fox J, Puyang X, Bracken K, et al.
Antimicrob Agents Chemother
. 2005 Jul;
49(8):3129-35.
PMID: 16048914
Haemophilus influenzae isolates vary widely in their susceptibilities to the peptide deformylase inhibitor LBM415 (MIC range, 0.06 to 32 microg/ml); however, on average, they are less susceptible than gram-positive organisms,...
10.
Raju B, Anandan S, Gu S, Herradura P, ODowd H, Kim B, et al.
Bioorg Med Chem Lett
. 2004 May;
14(12):3103-7.
PMID: 15149653
Deoxynegamycin (1b) is a protein synthesis inhibitor with activity against Gram-negative (GN) bacteria. A series of conformationally restricted analogs were synthesized to probe its bioactive conformation. Indeed, some of the...